Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURQUOISE-CPB
2014-001477-13Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in hepatitis C virus infection (2 cohorts), sponsored by AbbVie Inc. Primary endpoints: Sustained virologic response at 12 weeks after treatment and Safety. Started Jul 2014; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-001477-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001477-13.